Vericel Corporation 2022 Q3 Form 10-Q Summary
Business Context and Reporting Period
Vericel is a commercial-stage biopharmaceutical company marketing MACI for knee cartilage repair and Epicel for severe burns in the United States. It also holds North American rights to NexoBrid, a registration-stage burn debridement product. The filing covers the unaudited three and nine months ended September 30, 2022, compared with the corresponding 2021 periods.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Total revenue | $38.6 million | $34.5 million | $111.7 million | $108.6 million |
| Gross profit | $25.2 million | $22.1 million | $71.5 million | $72.0 million |
| Gross margin | 65.5% | 64.0% | 64.1% | 66.3% |
| Operating loss | $(6.8) million | $(5.0) million | $(23.1) million | $(12.0) million |
| Net loss | $(6.6) million | $(4.9) million | $(22.6) million | $(12.0) million |
| Net loss per share | $(0.14) | $(0.11) | $(0.48) | $(0.26) |
| Operating cash flow | Not separately provided | Not separately provided | $10.7 million | $18.5 million |
Q3 revenue increased 11.7%, while nine-month revenue increased 2.8%. Q3 operating and net losses widened despite higher revenue. Nine-month operating expenses were $94.7 million, up 12.7%, including $29.4 million of non-cash stock-based compensation versus $26.5 million in the prior-year period.
At September 30, 2022, cash and cash equivalents were $65.2 million, short-term and long-term investments totaled $67.5 million, and total liquidity including cash and investments was approximately $132.7 million. Total liabilities were $70.2 million, primarily operating lease liabilities. The company had no borrowings outstanding under its new revolving credit facility.
Revenue and Material Changes
- MACI revenue increased 29.8% to $31.0 million in Q3 and 15.4% to $85.6 million for the first nine months, driven by volume and price growth.
- Epicel revenue declined 25.6% to $7.3 million in Q3 and 20.2% to $25.4 million for the first nine months, reflecting lower volume and the inherent variability of severe-burn cases.
- NexoBrid revenue declined 71.4% to $0.2 million in Q3 and 74.0% to $0.7 million for the first nine months. BARDA’s quarterly procurement under its existing arrangement completed during Q3, although BARDA retains an option to procure additional quantities.
- Nine-month gross profit declined modestly because lower Epicel labor utilization, raw-material price increases, and higher external storage and manufacturing-facility costs offset MACI growth.
- Research and development expense increased 18.9% to $14.7 million for the first nine months, while selling, general and administrative expense increased 11.7% to $80.0 million. Increases reflected higher headcount, stock-based compensation, travel, physician engagement, educational programs, and facility-related depreciation.
- Cash provided by operations declined to $10.7 million from $18.5 million, while cash, cash equivalents and restricted cash decreased $3.3 million during the first nine months.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, investments, product-sale cash flows, and available borrowing capacity should support current operations for at least 12 months from issuance of the financial statements. The company nevertheless continues to report an accumulated deficit of $405.9 million and expects future losses.
- On July 29, 2022, Vericel entered into a five-year, $150.0 million senior secured revolving credit facility. Approximately $6.2 million of the $15.0 million letter-of-credit subfacility was utilized, and no revolver borrowings were outstanding at quarter-end. The facility includes financial and operational covenants and floating-rate borrowing provisions.
- Vericel and MediWound resubmitted the NexoBrid BLA on July 1, 2022. The FDA accepted the resubmission and established a January 1, 2023 PDUFA date. Approval remains uncertain following the prior complete response letter, which cited chemistry, manufacturing and controls, facility-inspection, clinical-study, and safety matters.
- The company entered into a Burlington, Massachusetts lease for approximately 126,000 square feet of future headquarters and manufacturing space. Expected monthly contractual payments range from approximately $0.6 million to $0.8 million, with an estimated tenant-improvement allowance of approximately $25.1 million.
- COVID-19 remains a risk to elective MACI procedures, staffing, customer access, shipping, manufacturing, and regulatory timelines. The company reported no material current supply-chain or shipping impact but maintains safety stock.
- Inflation, interest-rate increases, geopolitical instability, the war in Ukraine, supply-chain disruption, reimbursement and collection estimates, product concentration, regulatory approval, and fluctuating Epicel demand could materially affect results.
- The company reported no material ongoing litigation, regulatory proceedings, or government investigations and no material changes to previously disclosed risk factors other than risks related to the new credit facility, economic uncertainty, and NexoBrid approval.
Investor Verification Priorities
- Verify the sustainability of MACI volume and price growth and whether it can offset Epicel variability and the loss or reduction of BARDA-related NexoBrid revenue.
- Monitor operating-expense growth, stock-based compensation, gross-margin pressure, and the path toward operating profitability.
- Confirm the FDA’s action on the NexoBrid BLA resubmission and assess the financial impact of approval delays or denial.
- Review liquidity needs and the timing and cost of the Burlington facility, including lease obligations and tenant-improvement spending.
- Track compliance with the revolving-credit agreement’s covenants and the potential impact of SOFR-based interest rates if borrowings are initiated.
- Assess changes in MACI reimbursement and collection estimates; management noted that a 50-basis-point change in the estimated uncollectible percentage could change nine-month 2022 revenue by approximately $0.3 million.